Advanced Mammography Systems will again feature its Aurora 0.5-tesladedicated MR mammography scanner, which was unveiled at last year'smeeting (SCAN 11/23/94). AMS reached an agreement in Septemberto install the first beta-site Aurora at the University
Advanced Mammography Systems will again feature its Aurora 0.5-tesladedicated MR mammography scanner, which was unveiled at last year'smeeting (SCAN 11/23/94). AMS reached an agreement in Septemberto install the first beta-site Aurora at the University of TexasMedical Branch in Galveston. AMS filed for 510(k) clearance ofthe scanner earlier this year.
AMS parent Advanced NMR of Wilmington, MA, will display its latestwork in ultra-high-field MRI. The company has experienced somesuccess in placing 3-tesla and 4-tesla scanners at research sitesthrough a marketing relationship with GE Medical Systems.
Advanced NMR has also begun marketing its InstaScan echo-planarimaging package to vendors other than GE, with whom it had anexclusive OEM relationship until June of last year. ANMR willshow at its RSNA booth a new version of InstaScan with a gradienthead coil insert for neurological applications.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.